Combination medicines of this type are relevant for two key therapeutic domains: Hormonal Contraception and the treatment of moderate acne in women who elect to use an oral contraceptive. This dual-action profile plays a role in managing distressing symptoms alongside family planning needs.

Management of Heavy Bleeding and Painful Periods

This therapeutic domain addresses core gynaecological symptoms including heavy menstrual bleeding (menorrhagia) and severe menstrual pain (dysmenorrhea). By managing the hormonal environment, Larissa plays a role in managing cycle predictability and regularity, which contributes to improved comfort. It may also assist with managing menstrual blood loss and the functional strain associated with severe cramps. This supports the patient by easing the overall symptom load.

The medication is commonly used to help with symptoms of chronic pelvic discomfort, heavy menstrual flow, and moderate to severe acne vulgaris.

“Used in clinical settings where patients require supportive management for both cycle stability and disruptive hormone-related symptoms.”

---

Quick Fact: Relief for Menstrual Distress Larissa is relevant for easing symptoms that interfere with daily functioning, such as symptoms related to physical discomfort or functional strain associated with severe menstrual cramps.

Addressing Hormonally Driven Skin and Pelvic Symptoms

This cluster focuses on relief from symptoms driven by systemic hormonal factors. Larissa is commonly used to treat moderate to severe acne vulgaris and may be part of the symptomatic management plan for chronic pelvic discomfort associated with conditions like endometriosis. The treatment is commonly used to help ease the overall symptom burden, which supports general well-being and assists with maintaining functional stability.

Regulatory References

1. EMA Public Assessment Report

Who Can and Cannot Use Larissa?

Larissa is approved for use in women of reproductive age seeking hormonal contraception. Its use is also established for the conditional treatment of heavy menstrual bleeding and moderate acne in women who elect to use a combined oral contraceptive after other treatment failures.

---

Absolute Contraindications

Use of this medicine is strictly contraindicated in several populations due to unacceptable risk:

• Women with a current or past history of Venous or Arterial Thromboembolism (e.g., blood clots, stroke, heart attack) or hypercoagulopathies.
• Smokers over age 35 and patients with uncontrolled hypertension or diabetes with vascular symptoms.
• Patients with severe active liver disease or known sex-hormone influenced malignancies (e.g., breast cancer).
• Pregnancy is an absolute contraindication.

---

Age and Use Restrictions

The medicine is not indicated for use before menarche or in postmenopausal women. It is not recommended for use while nursing due to potential impact on milk supply. Use requires restriction postpartum (not started before 4 weeks) and before major surgery (discontinued 4 weeks prior). The safety and efficacy profile has not been fully established for women with a Body Mass Index (BMI) greater than 30 kg/m^2.

Larissa, a combined oral contraceptive containing ethinyl estradiol and levonorgestrel, can interact with other medications, potentially altering its effectiveness or increasing the risk of side effects.

Medications that May Decrease Larissa's Effectiveness

Certain medications can accelerate the metabolism of the contraceptive hormones in Larissa, which may lead to breakthrough bleeding or reduced contraceptive protection. In these cases, a non-hormonal backup birth control method should be considered.

Drug Class	Examples
Anticonvulsants	Carbamazepine, Phenytoin, Topiramate
Antibiotics	Rifampin, Griseofulvin
Antivirals	Certain HIV protease inhibitors
Herbal Supplements	St. John's wort (Hypericum perforatum)

Interactions that May Increase Hormone Levels

Taking Larissa with certain drugs may increase the concentration of its hormones in the blood, which could raise the risk of side effects like blood clots.

• Hepatitis C combination therapies: Use with ombitasvir/paritaprevir/ritonavir (with or without dasabuvir) is strictly contraindicated due to the potential for significant liver enzyme elevation.
• Other Medications: Some antifungals (e.g., fluconazole) or vitamin C supplements may increase ethinyl estradiol levels.

Impact on Other Medications

Larissa may also affect the action of other drugs, such as antidiabetic agents (which may require a dose adjustment) and certain medications like lamotrigine, whose concentration may be decreased.

Larissa acts through the modulation of specific alpha-receptor systems within neurological and physiological signaling pathways. Its activity occurs in biological processes characterized by overactive or dysregulated signaling.

Modulation of Specific alpha-Receptor Subtypes

Larissa's primary mechanistic focus is on modulating activity within defined alpha-receptor systems. It functions as an allosteric modulator, which alters the receptor's sensitivity and responsiveness to its natural signaling molecules. This interaction changes the receptor responsiveness, resulting in attenuation of signaling at the cellular level, which influences the affected pathway dynamics.

Interference with Downstream Molecular Cascades

The direct receptor modulation initiates a sequence of events that alters signaling dynamics in defined neural and humoral pathways. By reducing the initial receptor response, Larissa limits the subsequent signal transduction cascades inside the cell. This interference operates in contexts involving heightened pathway activation, reducing the consequences of overactive mediator activity on downstream signal propagation.

️ Adjustment of Regulatory Feedback Systems

Larissa's influence extends to engaging and adjusting regulatory feedback mechanisms within the targeted pathways. This activity results in the adjustment of feedback mechanisms, which contributes to the sustained modulation of pathway activity. This engagement is relevant in systems where targeted pathway adjustment is required, resulting in specific physiological effects that are downstream of the mechanistic action.

The use of Larissa (Dienogest/Ethinyl Estradiol) follows a strict cyclic, sequential regimen. The medicine is a tablet intended solely for oral use and must be swallowed whole, with or without liquid. The standard daily dose throughout the treatment period is one tablet.

Core Regimen and Administration Scope

Feature	Official Instruction Summary
Route of Administration	Oral.
Dosing Schedule	One tablet taken daily. Standard regimens are either 21 consecutive days of active tablets followed by a 7-day hormone-free interval, or a continuous 28-day course with varying active and inert tablets.
Timing Rules	The tablet must be taken at approximately the same time each day to maintain a consistent hormonal pattern. Intake may occur with or without food.

---

Procedural Requirements and Constraints

There are two main procedural constraints for proper use. First, tablets must be consumed in the precise order directed on the blister pack to ensure the sequential pattern of hormone delivery. Second, the administration is time-sensitive: if an active tablet intake is delayed by more than 12 hours, a specific procedural step is required to address the potential break in the hormonal cycle, often necessitating temporary use of a non-hormonal contraceptive method.

The medicine is indicated for use in women of reproductive age, including postpubertal adolescents, but is not intended for use before the onset of menstruation.

Research Evidence / Overview of Studies for Larissa

The research evidence for this combination oral contraceptive is described in scientific literature and official regulatory documents, based on studies that include Randomized Controlled Trials (RCTs), follow-up studies, and scientific meta-analyses. This summary describes the evidence that has been gathered for the medicine's main uses, focusing only on what the research explored and what the data show so far, without offering any clinical guidance or recommendations.

---

Evidence for Primary Indication: Hormonal Contraception

Research for pregnancy prevention is built on large, multinational RCTs and extensive observational studies conducted in healthy women of reproductive age. The key outcome researchers monitored was contraceptive efficacy, quantified using the Pearl Index. Trials reported measurements that contributed to a high-volume data set, which regulators rely on to characterize the intended action of the medication. Research also describes the monitoring of how studies examined cycle characteristics, including regularity and predictability.

However, long-term effects are not fully established regarding patient adherence in real-world settings. The evidence remains limited for the effects of using the medication over many years on subsequent fertility after women stop taking it.

---

Evidence for Management of Associated Symptoms

Research has explored the use of this combination for symptomatic uses, including moderate acne vulgaris, menorrhagia (heavy menstrual bleeding), and severe menstrual pain (dysmenorrhea).

For Acne Vulgaris, controlled trials monitored outcomes linked to inflammatory states on the skin, examining objective measures like acne lesion counts and the Global Assessment Score over several menstrual cycles. Research provides insight into patterns observed during the study period.

For Menstrual Symptoms, research examined menorrhagia in placebo-controlled trials involving women in the absence of underlying uterine pathology. Researchers monitored outcomes related to blood loss volume using the Pictorial Blood Loss Assessment Chart (PBAC). For severe menstrual pain, studies explored outcomes related to physical discomfort, monitoring changes in patient-reported pain intensity scores and analgesic use.

There is limited information available for menorrhagia linked to underlying structural uterine issues. The primary research was evaluated in healthy women of reproductive age, and data for certain groups remain limited in the published clinical trial summaries. Research findings describe group patterns, not personal outcomes.

Key Studies & References

1. Dienogest/Ethinylestradiol Public Assessment Report (Contraception and Acne Indications)

Common questions about Larissa (FAQ)

Q: Is Larissa considered a long-term medicine, or is it only for short-term use?

According to official product information, the medicine is described for continuous, daily use over extended periods for its primary indication of contraception. Monitoring and follow-up are important for the medicine's continued use, and these visits are often suggested on an annual basis in clinical practice.

Q: How quickly is Larissa expected to start having an effect?

Official guidance states that when a person begins using the medicine, the body requires a specified time, typically around nine days, before reliable contraceptive protection is established. Regulatory guidance suggests the use of an additional non-hormonal method during this initial starting period, as contraceptive protection may not be fully established immediately.

Q: What is the typical timeframe before a doctor might evaluate if Larissa is working?

Regulatory documents mention that follow-up visits for ongoing use of the medicine are often conducted annually, scheduled for every 12 months. Individual monitoring for response to treatment is necessary, and the appropriate timing will be determined by a healthcare professional.

Q: Is the dose of Larissa the same for everyone?

Official instructions consistently state that the daily dose is one tablet. The regimen is structured to involve one daily tablet intake, regardless of the condition being treated (such as contraception or acne). However, the overall hormonal pattern may vary slightly depending on the specific pack design used.

Q: What information is available about stopping or discontinuing Larissa?

Regulatory texts advise that the medicine should be discontinued, often about four weeks in advance, in the event of planned major surgery or long-term immobilization to reduce the risk of thromboembolism. Discontinuation of the medicine, especially for non-surgical reasons, should be reviewed with a healthcare professional.

Q: Can Larissa be used by teenagers or children?

Official documentation indicates the medicine may be used for contraception in teenage females who are postpubertal adolescents. The medicine is not indicated for use before the start of menstruation (menarche).

Q: Can Larissa cause changes in appetite or weight?

Official information lists increased weight as a common side effect of the medicine. Regulatory sources also note that decreased weight and increased appetite are listed as uncommon side effects.

Q: Is it normal to feel tired or dizzy when starting Larissa?

Official sources list fatigue (tiredness) as a common side effect and dizziness as an uncommon side effect. It is noted that many common side effects are often more noticeable when a person first starts taking the medicine and may lessen over the first few cycles.

Q: What should I know about taking Larissa if I am an older adult?

Official documentation states there is no relevant indication for the use of the medicine in elderly women, as its use is restricted to women of reproductive age. The medicine is not developed or intended for use in women who are postmenopausal.

Q: What if I forget to take a dose of Larissa?

Official patient information contains specific procedural steps to follow if an active tablet is missed, based on the specific time delay and the point in the menstrual cycle when the missed dose occurred. These procedures are described to help manage the situation when the consistent hormonal pattern is interrupted.

Q: Are there different forms of Larissa available, like tablets, capsules, or liquid?

Official documentation describes the product as a single-form tablet intended for oral use. Other forms, such as capsules or liquid, are not referenced in the regulatory information.

Q: How does Larissa relate to other treatments for the same condition?

For the official treatment of moderate acne, regulatory documents indicate that the medicine is used for women who choose to use an oral contraceptive after failure of suitable topical therapies or oral antibiotic treatment. This describes its place in a treatment sequence.

Q: What kind of research has been done on Larissa's safety profile?

The medicine's regulatory profile is built on data from various studies, including Randomised Controlled Trials (RCTs) and large-scale observational cohort studies. These studies monitor adverse events and safety outcomes, which are data points used to characterize the medication's safety profile.

Q: Does Larissa have any known effects on kidney or liver function?

Use is strictly contraindicated in patients who have severe active liver disease. The medicine’s safety information includes warnings regarding the potential for liver problems, and monitoring is part of the established use in certain circumstances.

Q: What evidence exists about Larissa's use during breastfeeding?

Official sources state there are no adequate studies in women to fully determine infant risk when this medication is used during breastfeeding. The medicine's use is subject to the lack of sufficient data, making it a restricted use during nursing.

Q: Are headaches a common side effect when first starting Larissa?

Headache is listed as a common side effect. Regulatory sources note that many common side effects, including gastrointestinal issues and bleeding changes, are often more noticeable when a person first starts taking the medicine, and these effects may reduce over the first few cycles.

Q: Do official materials mention any long-term effects of taking Larissa?

Official documents state that the long-term effects of the medicine are not fully established. Furthermore, evidence regarding its impact on subsequent fertility after discontinuation is limited in the current body of research.

Q: Is it necessary to avoid certain types of food while taking Larissa?

Official documents generally state the tablet can be taken with or without food. However, there is a specific caution regarding grapefruit or grapefruit juice, as consuming it may increase the medicine's active hormone levels in the blood.

Q: Is the name 'Larissa' the same as the chemical name of the medicine?

No. The name 'Larissa' is a trade name or brand name. The medicine's active ingredients are identified by their chemical names, which are Dienogest and Ethinyl Estradiol.

Q: What are the official warnings about using Larissa with herbal supplements?

Official warnings specifically advise that the herbal supplement St. John's wort (Hypericum perforatum) can reduce the contraceptive effectiveness of the medicine. It is warned that St. John’s wort should be avoided while using this medicine.

Q: How does the risk of side effects compare between different age groups?

Regulatory information specifically details the increased risk of serious cardiovascular side effects, such as blood clots, for women over the age of 35 who smoke. Outside of this warning, risk is generally assessed on individual factors.

Q: Does taking Larissa require any lifestyle changes?

Official warnings strongly advise women who use the medicine to not smoke, particularly if they are over the age of 35. This is due to a significantly increased risk of serious cardiovascular events.

Q: Is it possible to be allergic to the non-active ingredients in Larissa?

Official documents note that the medicine contains excipients, such as lactose, and is therefore contraindicated for use in patients with certain hereditary problems of sugar intolerance. The full list of non-active ingredients is available in the official product information.

Q: Why are people often told to avoid grapefruit juice while on this type of medicine?

The official caution regarding grapefruit juice is due to its potential to inhibit certain enzymes in the body. This inhibition can cause the medicine’s active hormone levels to increase in the blood, potentially raising the risk of side effects.

Q: Can Larissa be crushed or split?

Official instruction requires that the medicine must be swallowed whole for proper administration.

Larissa (drospirenone and ethinyl estradiol) must be stored under specific environmental controls to maintain its labeled stability.

Requirement	Official Regulatory Condition
Storage Temperature	Store at controlled room temperature, generally between 20 C and 25 C.
Handling/Protection	Keep in the original blister packaging and protect from moisture, heat, and freezing.
Child Safety	Store the medicine out of the reach of children and pets.
Disposal Method	Discard product after the expiration date. Unused medicine should be disposed of via a drug take-back program or by following the FDA's instructions for mixing it with an undesirable substance before discarding in the household trash. Do not flush down the toilet.

These official requirements ensure the product remains viable and prevent accidental exposure or environmental contamination.